Completed Trials

TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours

TARDOX :A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia

ATOM: Atovaquone as Tumour HypOxia Modifier

ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.

6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours

6MP: Phase II Clinical Trial Of 6-Mercaptopurine (6MP) And Low-Dose Methotrexate in Patients with known BRCA Defective Tumours

AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia

BKM120: Palliative thoracic radiotherapy plus BKM120

BKM120: A phase I dose escalation study of the PI3K inhibitor BKM120, given concomitantly with palliative radiotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC).

CHOP-OR: Study of CHOP with Ofatumumab in Patients with Richter's Syndrome

CHOP-OR: Phase 2 single arm multi-centre feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome

COG : Gefitinib for oesophageal cancer progressing after chemotherapy

COG: Randomised Phase 3 trial of gefitnib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy

DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring

DEBIOC: Dual Erb B Inhibition in Oesophago-gastric Cancer

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma